Palamedes Report on Mythryl: “Ofatumumab vs Ocrelizumab in Relapsing-Remitting Multiple Sclerosis…”

Ofatumumab vs Ocrelizumab in Relapsing-Remitting Multiple Sclerosis: A Nationwide Cohort Study. Neurology This week in Multiple Sclerosis and Neuroimmunology: palamedesreport.org/this-week/multiple-sclerosis pubmed.ncbi.nlm.nih.gov/42832743 #MedSky #neurology #multiplesclerosis

15/10/26, 1:00 pm0 reposts0 likes

Post